Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00207012 | MAD Refractory: Solid Tumor QD w/o Break | PHASE1 | COMPLETED | 45 | — | — | May 1, 2004 | - | Mar 2, 2010 | 2 | France, Spain |
| Name | Type | Description |
|---|---|---|
| BMS-599626 | DRUG | - |
Inclusion Criteria: * Signed written informed consent * Available for periodic follow-up * Life expectancy of at least 3 months * ECOG performance status score 0-1 * Histologic or cytologic diagnosis of a primary malignancy of breast, ovarian, bladder, gastric, non small cell lung or colon origin *...